Abstract
A non-invasive diagnostic approach is crucial for the evaluation of severity of liver disease, treatment decisions, and assessing drug efficacy. This study evaluated plasma proteomic profiling via an N-terminal isotope tagging strategy coupled with liquid chromatography/Fourier transform ion cyclotron resonance mass spectrometry measurement to detect liver fibrosis staging. Pooled plasma from different liver fibrosis stages, which were assessed in advance by the current gold-standard of liver biopsy, was quantitatively analyzed. A total of 72 plasma proteins were found to be dysregulated during the fibrogenesis process, and this finding constituted a valuable candidate plasma biomarker bank for follow-up analysis. Validation results of fibronectin by Western blotting reconfirmed the mass-based data. Ingenuity Pathways Analysis showed four types of metabolic networks for the functional effect of liver fibrosis disease in chronic hepatitis B patients. Consequently, quantitative proteomics via the N-terminal acetyl isotope labeling technique provides an effective and useful tool for screening plasma candidate biomarkers for liver fibrosis. We quantitatively monitored the fibrogenesis process in CHB patients. We discovered many new valuable candidate biomarkers for the diagnosis of liver fibrosis and also partly identified the mechanism involved in liver fibrosis disease. These results provide a clearer understanding of liver fibrosis pathophysiology and will also hopefully lead to improvement of clinical diagnosis and treatment.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Lee W M. Hepatitis B virus infection. N Engl J Med, 1997, 337: 1733–1745 9392700, 10.1056/NEJM199712113372406, 1:STN:280:DyaK1c%2FktFyjtA%3D%3D
Lok A S, McMahon B J. Chronic hepatitis B. Hepatology, 2001, 34: 1225–1241 11732013, 10.1053/jhep.2001.29401, 1:STN:280:DC%2BD3MnosV2qtw%3D%3D
Afdhal N H, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol, 2004, 99: 1160–1174 15180741, 10.1111/j.1572-0241.2004.30110.x
Friedman S L. Liver fibrosis—from bench to bedside. J Hepatol, 2003, 38: S38–53 12591185, 10.1016/S0168-8278(02)00429-4
Smith J O, Sterling R K. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther, 2009, 30: 557–576 19519733, 10.1111/j.1365-2036.2009.04062.x, 1:STN:280:DC%2BD1MrnsVKrsw%3D%3D
Beretta L. Comparative analysis of the liver and plasma proteomes as a novel and powerful strategy for hepatocellular carcinoma biomarker discovery. Cancer Lett, 2009, 286: 134–139 19232462, 10.1016/j.canlet.2009.01.025, 1:CAS:528:DC%2BD1MXhtlygs7zJ
Ong S E, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol, 2005, 1: 252–262 16408053, 10.1038/nchembio736, 1:CAS:528:DC%2BD2MXhtVamtrfI
Tao W A, Aebersold R. Advances in quantitative proteomics via stable isotope tagging and mass spectrometry. Curr Opin Biotechnol, 2003, 14: 110–118 12566010, 10.1016/S0958-1669(02)00018-6, 1:CAS:528:DC%2BD3sXps1WltQ%3D%3D
Wu S, Kaiser N K, Meng D, et al. Increased protein identification capabilities through novel tandem MS calibration strategies. J Proteome Res, 2005, 4: 1434–1441 16083297, 10.1021/pr0501057, 1:CAS:528:DC%2BD2MXlvVahsbs%3D
Scheuer P J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol, 1991, 13: 372–374 1808228, 10.1016/0168-8278(91)90084-O, 1:STN:280:DyaK383is1CrtQ%3D%3D
Beardsley R L, Reilly J P. Optimization of guanidination procedures for MALDI mass mapping. Anal Chem, 2002, 74: 1884–1890 11985322, 10.1021/ac015613o, 1:CAS:528:DC%2BD38XhslOgt7w%3D
Ji C, Guo N, Li L. Differential dimethyl labeling of N-termini of peptides after guanidination for proteome analysis. J Proteome Res, 2005, 4: 2099–2108 16335955, 10.1021/pr050215d, 1:CAS:528:DC%2BD2MXhtFynu7fM
Jia N, Liu X, Wen J, et al. A proteomic method for analysis of CYP450s protein expression changes in carbon tetrachloride induced male rat liver microsomes. Toxicology, 2007, 237: 1–11 17606319, 10.1016/j.tox.2007.04.015, 1:CAS:528:DC%2BD2sXnslWntbc%3D
Meneses-Lorente G, Watt A, Salim K, et al. Identification of early proteomic markers for hepatic steatosis. Chem Res Toxicol, 2006, 19: 986–998 16918237, 10.1021/tx060007f, 1:CAS:528:DC%2BD28XmvFWht7c%3D
Nedelkov D, Kiernan U A, Niederkofler E E, et al. Investigating diversity in human plasma proteins. Proc Natl Acad Sci USA, 2005, 102): 10852–10857 16043703, 10.1073/pnas.0500426102, 1:CAS:528:DC%2BD2MXnvVWjtrw%3D
Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology, 2005, 41: 1376–1382 15915455, 10.1002/hep.20717
Rockey D C, Bissell D M. Noninvasive measures of liver fibrosis. Hepatology, 2006, 43: S113–120 16447288, 10.1002/hep.21046, 1:CAS:528:DC%2BD28XhvVSktLg%3D
Everley P A, Bakalarski C E, Elias J E, et al. Enhanced analysis of metastatic prostate cancer using stable isotopes and high mass accuracy instrumentation. J Proteome Res, 2006, 5: 1224–1231 16674112, 10.1021/pr0504891, 1:CAS:528:DC%2BD28Xjs1Gmsr0%3D
Koumenis I L, Vestal M L, Yergey A L, et al. Quantitation of metal isotope ratios by laser desorption time-of-flight mass spectrometry. Anal Chem, 1995, 67: 4557–4564 8633789, 10.1021/ac00120a020, 1:CAS:528:DyaK2MXpt1agurs%3D
Noga M J, Asperger A, Silberring J. N-terminal H3/D3-acetylation for improved high-throughput peptide sequencing by matrix-assisted laser desorption/ionization mass spectrometry with a time-of-flight/time-of-flight analyzer. Rapid Commun Mass Spectrom, 2006, 20: 1823–1827 16705653, 10.1002/rcm.2522, 1:CAS:528:DC%2BD28XmtFWjtrg%3D
Zappacosta F, Annan R S. N-terminal isotope tagging strategy for quantitative proteomics: results-driven analysis of protein abundance changes. Anal Chem, 2004, 76: 6618–6627 15538785, 10.1021/ac049169b, 1:CAS:528:DC%2BD2cXotlartbw%3D
Burt A D. C. L. Oakley Lecture. Cellular and molecular aspects of hepatic fibrosis. J Pathol, 1993, 170: 105–114 8345406, 10.1002/path.1711700203, 1:STN:280:DyaK3szkslSnsA%3D%3D
Azuma T, Koths K, Flanagan L, et al. Gelsolin in complex with phosphatidylinositol 4,5-bisphosphate inhibits caspase-3 and -9 to retard apoptotic progression. J Biol Chem, 2000, 275: 3761–3766 10660524, 10.1074/jbc.275.6.3761, 1:CAS:528:DC%2BD3cXht12hu70%3D
Neubauer K, Baruch Y, Lindhorst A, et al. Gelsolin gene expression is upregulated in damaged rat and human livers within non-parenchymal cells and not in hepatocytes. Histochem Cell Biol, 2003, 120: 265–275 14574581, 10.1007/s00418-003-0564-x, 1:CAS:528:DC%2BD3sXot1Oqt7g%3D
Suhler E, Lin W, Yin H L, et al. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med, 1997, 25: 594–598 9142022, 10.1097/00003246-199704000-00007, 1:STN:280:DyaK2s3os12gsg%3D%3D
Attallah A M, Zahran F, Ismail H, et al. Immunochemical identification and detection of serum fibronectin in liver fibrosis patients with chronic hepatitis C. J Immunoassay Immunochem, 2007, 28: 331–342 17885887, 10.1080/15321810701603476, 1:CAS:528:DC%2BD2sXhtVGktbjO
Grieco A, Matera A, Di Rocco P, et al. Plasma levels of fibronectin in patients with chronic viral and alcoholic liver disease. Hepatogastroenterology, 1998, 45: 1731–1736 9840137, 1:STN:280:DyaK1M%2FltlyksA%3D%3D
Perez Blanco F J, Rodriguez Cuartero A, Nunez Carril J, et al. Haptoglobin and hemopexin in the chronic hepatopathies. Rev Esp Enferm Apar Dig, 1982, 62: 20–24 7100594, 1:STN:280:DyaL383kvFSmtw%3D%3D
Poli V, Silengo L, Altruda F, et al. The analysis of the human hemopexin promoter defines a new class of liver-specific genes. Nucleic Acids Res, 1989, 17: 9351–9365 2555791, 1:CAS:528:DyaK3cXjtFGrsQ%3D%3D
Ratra R, Kar-Roy A, Lal S K. The ORF3 protein of hepatitis E virus interacts with hemopexin by means of its 26 amino acid N-terminal hydrophobic domain II. Biochemistry, 2008, 47: 1957–1969 18211098, 10.1021/bi7016552, 1:CAS:528:DC%2BD1cXptl2gsA%3D%3D
Koukoulis G K, Shen J, Virtanen I, et al. Vitronectin in the cirrhotic liver: an immunomarker of mature fibrosis. Hum Pathol, 2001, 32: 1356–1362 11774169, 10.1053/hupa.2001.29675, 1:CAS:528:DC%2BD38XmvVKmtQ%3D%3D
Yamada S, Kobayashi J, Murawaki Y, et al. Collagen-binding activity of plasma vitronectin in chronic liver disease. Clin Chim Acta, 1996, 252: 95–103 8814365, 10.1016/0009-8981(96)06320-6, 1:CAS:528:DyaK28XksFCmsro%3D
Fan C, Stendahl U, Stjernberg N, et al. Association between orosomucoid types and cancer. Oncology, 1995, 52: 498–500 7478438, 10.1159/000227518, 1:STN:280:DyaK28%2Fmt1Wjuw%3D%3D
Sorensson J, Matejka G L, Ohlson M, et al. Human endothelial cells produce orosomucoid, an important component of the capillary barrier. Am J Physiol, 1999, 276: H530–534 9950854, 1:CAS:528:DyaK1MXhtlCktrs%3D
Lovat L B, Persey M R, Madhoo S, et al. The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut, 1998, 42: 727–734 9659172, 10.1136/gut.42.5.727, 1:STN:280:DyaK1czitlejug%3D%3D
Levo Y, Shalit M, Tur-Kaspa R. Serum amyloid P-component as a marker of liver disease. Am J Gastroenterol, 1982, 77: 427–430 7091128, 1:CAS:528:DyaL38Xks1yksLw%3D
Munthe-Fog L, Hummelshoj T, Honore C, et al. Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. N Engl J Med, 2009, 360: 2637–2644 19535802, 10.1056/NEJMoa0900381, 1:CAS:528:DC%2BD1MXntlKiu7c%3D
Le Y, Lee S H, Kon O L, et al. Human L-ficolin: plasma levels, sugar specificity, and assignment of its lectin activity to the fibrinogen-like (FBG) domain. FEBS Lett, 1998, 425: 367–370 9559681, 10.1016/S0014-5793(98)00267-1, 1:CAS:528:DyaK1cXhvFGqtbo%3D
Enjyoji K, Kato H. Purification and characterization of two isoforms of T-kininogens from rat liver microsomes. J Biochem, 1992, 111: 670–675 1639765, 1:CAS:528:DyaK38XisFSqsbk%3D
Giannelli G, Antonaci S. Immunological and molecular aspects of liver fibrosis in chronic hepatitis C virus infection. Histol Histopathol, 2005, 20: 939–944 15944944, 1:CAS:528:DC%2BD2MXpsFKjt7c%3D
Mehta A S, Long R E, Comunale M A, et al. Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol, 2008, 82: 1259–1270 18045939, 10.1128/JVI.01600-07, 1:CAS:528:DC%2BD1cXhtFOktLo%3D
Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol, 2006, 6: 6 16503961, 10.1186/1471-230X-6-6
Gobel T, Vorderwulbecke S, Hauck K, et al. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol, 2006, 12: 7604–7612 17171788
West R B, Harvell J, Linn S C, et al. Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. Am J Surg Pathol, 2004, 28: 1063–1069 15252314, 10.1097/01.pas.0000126857.86186.4c
Otogawa K, Kinoshita K, Fujii H, et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. Am J Pathol, 2007, 170: 967–980 17322381, 10.2353/ajpath.2007.060441, 1:CAS:528:DC%2BD2sXjs1WlsLk%3D
Poon T C, Hui A Y, Chan H L, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem, 2005, 51: 328–335 15590748, 10.1373/clinchem.2004.041764, 1:CAS:528:DC%2BD2MXhtVGhu7g%3D
Arteel G E. “HOPE” for the liver? Mechanistic insight into the role of the renin-angiotensin system in hepatic fibrosis. Hepatology, 2004, 40: 263–265 15239111, 10.1002/hep.20296, 1:CAS:528:DC%2BD2cXmtlSgu7w%3D
Xiao F, Wei H, Song S, et al. Polymorphisms in the promoter region of the angiotensinogen gene are associated with liver cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol, 2006, 21: 1488–1491 16911698, 1:CAS:528:DC%2BD28XhtVOqtLbK
Schiavon L L, Schiavon J L, Filho R J, et al. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology, 2007, 46: 307–314 17634962, 10.1002/hep.21681
Mohamadnejad M, Montazeri G, Fazlollahi A, et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol, 2006, 101: 2537–2545 17029616
Lebensztejn D M, Skiba E, Sobaniec-Lotowska M, et al. A simple noninvasive index (APRI) predicts advanced liver fibrosis in children with chronic hepatitis B. Hepatology, 2005, 41: 1434–1435 15915470, 10.1002/hep.20736
Murata C, Watanabe T, Furuya H, et al. Aldehyde dehydrogenase 2 and β3-adrenergic receptor gene polymorphisms: their association with elevated liver enzymes and metabolic syndrome. Metabolism, 2003, 52: 1096–1101 14506613, 10.1016/S0026-0495(03)00183-5, 1:CAS:528:DC%2BD3sXntVGlu74%3D
Enomoto N, Takase S, Takada N, et al. Alcoholic liver disease in heterozygotes of mutant and normal aldehyde dehydrogenase-2 genes. Hepatology, 1991, 13: 1071–1075 2050324, 10.1002/hep.1840130611, 1:STN:280:DyaK3M3mslClsA%3D%3D
Ferre N, Marsillach J, Camps J, et al. Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. Clin Chim Acta, 2005, 361: 206–210 15993873, 10.1016/j.cccn.2005.05.024, 1:CAS:528:DC%2BD2MXhtVGrsLbJ
Shirai R, Hirano F, Ohkura N, et al. Up-regulation of the expression of leucine-rich α(2)-glycoprotein in hepatocytes by the mediators of acute-phase response. Biochem Biophys Res Commun, 2009, 382: 776–779 19324010, 10.1016/j.bbrc.2009.03.104, 1:CAS:528:DC%2BD1MXkslymtL8%3D
Heo S H, Lee S J, Ryoo H M, et al. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics, 2007, 7: 4292–4302 17963278, 10.1002/pmic.200700433, 1:CAS:528:DC%2BD2sXhsVOqsL7O
de Sa S V, Correa-Giannella M L, Machado M C, et al. Serpin peptidase inhibitor clade A member 1 as a potential marker for malignancy in insulinomas. Clin Cancer Res, 2007, 13: 5322–5330 17855650, 10.1158/1078-0432.CCR-06-1477
Sathe S, Sakata M, Beaton A R, et al. Identification, origins and the diurnal role of the principal serine protease inhibitors in human tear fluid. Curr Eye Res, 1998, 17: 348–362 9561826, 10.1080/02713689808951215, 1:STN:280:DyaK1c3it1Kguw%3D%3D
Jiang H Y, Wang S X, Li X H, et al. The proteomics research on relational expressed serum proteins among the recovered SARS patients complicating avascular necrosis of femoral head (in Chinese). Zhonghua Yu Fang Yi Xue Za Zhi, 2008, 42: 522–526 19035190, 1:CAS:528:DC%2BD1MXhtVantbnL
Zhou M, Shen D, Head J E, et al. Ocular clusterin expression in von Hippel-Lindau disease. Mol Vis, 2007, 13: 2129–2136 18079682
Rodriguez-Pineiro A M, de la Cadena M P, Lopez-Saco A, et al. Differential expression of serum clusterin isoforms in colorectal cancer. Mol Cell Proteomics, 2006, 5: 1647–1657 16854844, 10.1074/mcp.M600143-MCP200, 1:CAS:528:DC%2BD28XpvVGgu78%3D
Chen X, Halberg R B, Ehrhardt W M, et al. Clusterin as a biomarker in murine and human intestinal neoplasia. Proc Natl Acad Sci USA, 2003, 100: 9530–9535 12886021, 10.1073/pnas.1233633100, 1:CAS:528:DC%2BD3sXmtlyku70%3D
Kang Y K, Hong S W, Lee H, et al. Overexpression of clusterin in human hepatocellular carcinoma. Hum Pathol, 2004, 35: 1340–1346 15668890, 10.1016/j.humpath.2004.07.021, 1:CAS:528:DC%2BD2cXhtVKltLrP
Meistermann H, Norris J L, Aerni H R, et al. Biomarker discovery by imaging mass spectrometry: transthyretin is a biomarker for gentamicin-induced nephrotoxicity in rat. Mol Cell Proteomics, 2006, 5: 1876–1886 16705188, 10.1074/mcp.M500399-MCP200, 1:CAS:528:DC%2BD28XhtFGqsbfM
Biroccio A, Del Boccio P, Panella M, et al. Differential post-translational modifications of transthyretin in Alzheimer’s disease: a study of the cerebral spinal fluid. Proteomics, 2006, 6: 2305–2313 16552785, 10.1002/pmic.200500285, 1:CAS:528:DC%2BD28Xjslyrtrg%3D
Barcelo-Batllori S, Kalko S G, Esteban Y, et al. Integration of DIGE and bioinformatics analyses reveals a role of the antiobesity agent tungstate in redox and energy homeostasis pathways in brown adipose tissue. Mol Cell Proteomics, 2008, 7: 378–393 17986440, 1:CAS:528:DC%2BD1cXitlyltrk%3D
Saile B, Ramadori G. Inflammation, damage repair and liver fibrosis—role of cytokines and different cell types. Z Gastroenterol, 2007, 45: 77–86 17236124, 10.1055/s-2006-927395, 1:CAS:528:DC%2BD2sXislCht7Y%3D
Kershenobich Stalnikowitz D, Weissbrod A B. Liver fibrosis and inflammation. A review. Ann Hepatol, 2003, 2: 159–163
Yip T T, Cho W C, Cheng W W, et al. Application of ProteinChip array profiling in serum biomarker discovery for patients suffering from severe acute respiratory syndrome. Methods Mol Biol, 2007, 382: 313–331 18220240, 10.1007/978-1-59745-304-2_20, 1:CAS:528:DC%2BD2sXpsleitbg%3D
Spisak S, Tulassay Z, Molnar B, et al. Protein microchips in biomedicine and biomarker discovery. Electrophoresis, 2007, 28: 4261–4273 17979160, 10.1002/elps.200700539, 1:CAS:528:DC%2BD1cXksFKmug%3D%3D
Zhang G, Terry A V Jr, Bartlett M G. Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat plasma. Rapid Commun Mass Spectrom, 2007, 21: 920–928 17295424, 10.1002/rcm.2914, 1:CAS:528:DC%2BD2sXjsVSnsbw%3D
Kim K, Kim S J, Yu H G, et al. Verification of biomarkers for diabetic retinopathy by multiple reaction monitoring. J Proteome Res, 2010, 9: 689–699 20020744, 10.1021/pr901013d, 1:CAS:528:DC%2BD1MXhsFOgtLfK
Boersema P J, Raijmakers R, Lemeer S, et al. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat Protoc, 2009, 4: 484–494 19300442, 10.1038/nprot.2009.21, 1:CAS:528:DC%2BD1MXjvFyjs7g%3D
Author information
Authors and Affiliations
Corresponding authors
Additional information
Contributed equally to this work
This article is published with open access at Springerlink.com
Electronic supplementary material
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Li, S., Liu, X., Wei, L. et al. Plasma biomarker screening for liver fibrosis with the N-terminal isotope tagging strategy. Sci. China Life Sci. 54, 393–402 (2011). https://doi.org/10.1007/s11427-011-4165-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-011-4165-y